Twist Bioscience Corporation (TWST)

Market Cap	3.01B -1.2%
Revenue (ttm)	391.56M +18.6%
Net Income	-76.58M
EPS	-1.27
Shares Out	61.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,063,343
Open	47.62
Previous Close	47.66
Day's Range	47.62 - 50.17
52-Week Range	23.30 - 51.00
Beta	2.27
Analysts	Buy
Price Target	50.22 (+2.26%)
Earnings Date	Feb 2, 2026

About TWST

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 31, 2018
• Employees: 979
• Stock Exchange: NASDAQ
• Ticker Symbol: TWST
• Website: https://www.twistbioscience.com

Financial Performance

In fiscal year 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.

Analyst Summary

According to 9 analysts, the average rating for TWST stock is "Buy." The 12-month stock price target is $50.22, which is an increase of 2.26% from the latest price.

Price Target

$50.22

(2.26% upside)

Analyst Consensus: Buy